The classic laboratory finding in patients with multiple myeloma is hyperglobulinemia, which results from the excessive production of immunoglobulin or an immunoglobulin subunit by the neoplastic cells. This homogeneous protein fraction is often calledparaproteinorM protein. Paraproteins produced from the sa...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
This treatment is not approved for multiple myeloma yet, but it is being tested to see how safe it is and how well it works. CAR T stands for chimeric antigen receptor (CAR) T-cell therapy. Doctors take some of your blood and remove the T cells, which are considered workhorses of you...
Myeloma is the second most common blood cancer, but it is not a common cancer. An estimated 32,110 new patients will be diagnosed with myeloma in the United States in 2019, and men are diagnosed with the condition slightly more frequently than women. The mortality statistic in the U.S. i...
- 《Blood》 被引量: 1404发表: 2011年 Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation Autologous hematopoietic stem cell transplantation was used for treatment of 384 patients with multiple myeloma in 37 centers during the years ...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Results Sixteen WTC-exposed white male firefighters received a diagnosis of multiple myeloma after September 11, 2001; median age at diagnosis was 57 years (interquartile range, 50-68 years). Serum/urine monoclonal protein isotype/free light-chain data were available for 14 cases; 7 (50%) had...
Multiple myeloma (MM) is still incurable partially due to lacking effective therapeutic targets. Aberrant N6-methyladenosine (m6A) RNA modification plays a vital role in many cancers, however few researches are executed in MM. We first screened the m6A-r
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
“The diagnosis, workup, and treatment of myeloma have dramatically changed over the past 10 years. The therapeutic goal is to obtain deep remissions that translate into improved progression-free and overall survival. With combination therapy using immunomodulatory drugs, proteasome inhibitors, monoclonal...